GSK

GSK plc GSK

NYSEMega CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #1,331 of 2,925TOP 50%

Why it scores 54Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$32.67B

Quarter to Dec 31

Net income

$5.72B

Quarter to Dec 31

Free cash flow

$6.39B

Quarter to Dec 31

Operating margin

24.3%

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$18.30B total
FMR LLC
$3.41B-4.0%
DODGE & COX
$2.53B-17.8%
Fisher Asset Management, LLC
$1.87B+3.5%
PRIMECAP MANAGEMENT CO/CA/
$1.32B-0.1%
WELLINGTON MANAGEMENT GROUP LLP
$597.39M-2.7%
JTC Employer Solutions Trusteee Ltd
$450.31M-5.0%
MORGAN STANLEY
$401.41M-30.6%
ROYAL BANK OF CANADA
$397.81M+1.1%
PRICE T ROWE ASSOCIATES INC /MD/
$362.94M-5.5%
ACADIAN ASSET MANAGEMENT LLC
$349.11M-43.5%
GOLDMAN SACHS GROUP INC
$333.99M-33.6%
STATE STREET CORP
$315.14M-0.7%
Mondrian Investment Partners LTD
$257.43M-1.5%
BANK OF MONTREAL /CAN/
$211.93M-12.9%
BlackRock, Inc.
$189.78M+2.0%
Grantham, Mayo, Van Otterloo & Co. LLC
$188.69M+2.2%
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC
$178.94M-2.0%
EQUITY INVESTMENT CORP
$171.40M+1.5%
UBS Group AG
$147.10M+34.6%
Aristotle Capital Management, LLC
$145.97M-5.9%
Connor, Clark & Lunn Investment Management Ltd.
$145.08M-1.8%
DIMENSIONAL FUND ADVISORS LP
$141.10M+4.1%
Point72 Asset Management, L.P.
$139.06MNew
BANK OF AMERICA CORP /DE/
$116.21M+0.5%
JPMORGAN CHASE & CO
$110.11M+260.2%
See all 1,055 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Operating Margin

FY 2025
EDGAR

ROIC

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Loading ratio trend…

GSK key financials by period

Reported revenue, net income and operating margin by fiscal year, from GSK plc's annual filings on SEC EDGAR.

GSK plc reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$32.7B$5.7B24.3%
FY 2024$31.4B$2.6B12.8%
FY 2023$30.3B$4.9B22.2%
FY 2022$29.3B$15.0B21.9%
FY 2021$24.7B$4.4B17.6%
FY 2020$24.4B$5.7B24.6%
Source: GSK filings on SEC EDGAR →

Companies similar to GSK

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

Congress trading in GSK

26 transactions in GSK reported by 10 members of Congress under the STOCK Act, most recent trade Oct 31, 2025. Reported transactions, not recommendations.

All Congress stock trades →

About GSK plc (GSK): stock profile, AI score and financials

GSK plc (GSK) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GSK at 54.3/100 on a composite quality score built from its SEC filings, placing it at rank #1,331 of 2,925 stocks — the top half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), GSK plc reports quarterly revenue of $32.7B, net income of $5.7B, an operating margin of 24.3%. Top institutional holders of GSK by reported 13-F value include FMR, DODGE & COX, Fisher Asset Management, based on the most recent SEC filings. GSK trades on the NYSE exchange and files with the SEC under CIK 1131399. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GSK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GSK plc directly from SEC EDGAR.

SEC EDGAR: CIK 1131399 →